- Home
- GXAI vs NRSN Comparison
GXAI vs NRSN Comparison
Compare GXAI & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | NRSN |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.6M | 7.6M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GXAI | NRSN |
|---|---|---|
| Price | $0.43 | $3.05 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $78.50 |
| AVG Volume (30 Days) | ★ 165.0K | 15.7K |
| Earning Date | 11-12-2026 | 09-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 71.35 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,933,030.00 | N/A |
| Revenue This Year | $462.16 | N/A |
| Revenue Next Year | $30.00 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 47901.74 | N/A |
| 52 Week Low | $0.42 | $0.25 |
| 52 Week High | $5.26 | $7.50 |
Technical Indicators
Market Signals| Indicator | GXAI | NRSN |
|---|---|---|
| Relative Strength Index (RSI) | 26.01 | 41.70 |
| Support Level | $0.42 | $0.63 |
| Resistance Level | $2.58 | $7.50 |
| Average True Range (ATR) | 0.03 | 0.46 |
| MACD | 0.01 | -0.33 |
| Stochastic Oscillator | 1.65 | 7.49 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is a technology company focused on reshaping the way people interact with artificial intelligence across everyday life and high-impact industries. It is engaged in building a portfolio of AI-powered solutions designed to make advanced technology more practical, accessible, and transformative. The company's portfolio spans defense, health and wellness, entertainment, and productivity - bringing intelligent tools to markets where innovation can drive meaningful real-world outcomes. It operates as a single operating segment technology-based company that is developing applications aimed at redefining the way it utilizes artificial intelligence (AI) to optimize the user experience.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.